Alvotech Shares Plunge to New 52-Week Low at $3.78

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.78 as of March 2, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 72.61%, contrasting sharply with the S&P 500's gain of 17.36% during the same period. The company's market capitalization stands at USD 1,238 million, and it currently has a price-to-earnings (P/E) ratio of 41.00. Alvotech has not offered any dividends, reflected in its 0.00% dividend yield. Financial metrics indicate a challenging landscape, with a negative book value of -7.00 and a return on equity of -39.32%. Additionally, the company's debt equity ratio is reported at -6.19, suggesting difficulties in managing its financial obligations. Despite a notable annual growth rate in net sales of 256.02% and operating profit growth of 37.21% over the last five years, Alvotech's ability to service its debt remains a concern, highlighted by a poor EBIT to interest ratio of -7.56. This combination of factors has contributed to the stock's consistent underperformance against market benchmarks.